Cytosorbents (CTSO) Income towards Parent Company (2010 - 2026)
Cytosorbents (CTSO) posted Income towards Parent Company of -$11.0 million for Q1 2026, down 169.79% on a QoQ basis from -$4.1 million in Q4 2025, and down 646.77% year-over-year from $2.0 million in Q1 2025.
Cytosorbents (CTSO) Income towards Parent Company (2010 - 2026) Analysis & Trends
Cytosorbents' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$11.0 million for Q1 2026.
- Quarterly Income towards Parent Company fell 646.77% year-over-year to -$11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.5 million (down 892.28% YoY) and the FY2025 annual result came in at -$6.8 million, up 24.49% from the prior year.
- Income towards Parent Company was -$11.0 million for Q1 2026 at Cytosorbents, down from -$4.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $4.2 million in Q4 2024 and bottomed at -$25.2 million in Q2 2025.
- A 5-year average of -$6.8 million and a median of -$6.1 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company tumbled 700.76% — and 2024, when it surged 167.74%.
- Cytosorbents' Income towards Parent Company stood at -$766126.0 in 2022, then plunged by 700.76% to -$6.1 million in 2023, then jumped by 167.74% to $4.2 million in 2024, then tumbled by 198.46% to -$4.1 million in 2025, then sank by 169.79% to -$11.0 million in 2026.
- Business Quant data shows CTSO's Income towards Parent Company at -$11.0 million in Q1 2026, -$4.1 million in Q4 2025, and -$3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Cytosorbents | 23.04 Mn | 18.24 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.04 Mn |
| Dec 31, 2025 | -4.09 Mn |
| Sep 30, 2025 | -3.17 Mn |
| Jun 30, 2025 | -25.21 Mn |
| Mar 31, 2025 | -1.48 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Sep 30, 2024 | -2.77 Mn |
| Jun 30, 2024 | -4.30 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Dec 31, 2023 | -6.13 Mn |
| Sep 30, 2023 | -9.19 Mn |
| Jun 30, 2023 | -6.60 Mn |
| Mar 31, 2023 | -7.32 Mn |
| Dec 31, 2022 | -766,126.00 |
| Sep 30, 2022 | -12.20 Mn |
| Jun 30, 2022 | -10.88 Mn |
| Mar 31, 2022 | -8.97 Mn |
| Dec 31, 2021 | -9.31 Mn |
| Sep 30, 2021 | -6.41 Mn |
| Jun 30, 2021 | -4.68 Mn |